

ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies

ReEngage partners with globally-recognized cancer center to study ACSS2 and its role in acetate metabolism, histone modification and DNA Damage Response



HOUSTON, TX, USA, July 9, 2024

[/EINPresswire.com/](https://www.einpresswire.com/) -- ReEngage

Therapeutics, a biotech company pioneering epigenetics to treat

longevity-related diseases, today announced the execution of a Sponsored Research Agreement with [The University of Texas MD Anderson Cancer Center](#) to support research with the goal of developing ACSS2 inhibitors to treat cancer.

Under the agreement, ReEngage will support Eyal Gottlieb, PhD, Vice President of Research and Professor of Cancer Biology at MD Anderson, to study the effects of ACSS2 inhibitors on acetate metabolism, histone modifications and DNA damage response. These compounds, recently licensed from EpiVario, Inc., showed benefits in patient derived xenograft models with high ACSS2 expression. This preclinical research included ACSS2 inhibitors as a single agent in colorectal and triple negative breast cancers and in combination with platinum in gastric, ovarian, and non-small cell lung cancers.

ReEngage believes that this research has the potential to identify ACSS2 inhibitor compounds with potentially high efficacy in treating several different tumor types, both as a monotherapy and in combination with chemotherapy.

"ReEngage Therapeutics looks forward to building on the impressive preclinical data and Phase I clinical data already generated with our ACSS2 inhibitors," said Thomas Kim, CEO and co-founder of ReEngage. "By studying the specific mechanisms of action for these compounds that affect tumor development and growth, we expect to advance the best molecules forward to study their therapeutic potential in clinical trials."

DISCLOSURE

Dr. Gottlieb is a co-founder of ReEngage Therapeutics. His financial relationship with ReEngage is managed and monitored by the MD Anderson Conflict of Interest Committee.

ABOUT REENGAGE THERAPEUTICS

ReEngage Therapeutics aims to extend lifespan by modifying epigenetic targets in longevity-related diseases. The company has a portfolio of ACSS2 inhibitors that it licensed from Epivario Inc. for oncology. ReEngage's research combines metabolomics and genetic approaches to discover and pharmacologically exploit cancer-specific essential metabolic pathways.

For further information, please visit <https://www.reengagetx.com>. Follow ReEngage on Twitter at @ReEngageTx and on LinkedIn at <https://www.linkedin.com/company/reengage-therapeutics/>.

Thomas Kim

ReEngage Therapeutics Inc.

info@reengagetx.com

Visit us on social media:

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/726047983>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.